β-TCP porous pellets as an orthopaedic drug delivery system: ibuprofen/carrier physicochemical interactions
Source abstract
Abstract
Calcium phosphate bone substitute materials can be loaded with active substances for in situ, targeted drug administration. In this study, porous β-TCP pellets were investigated as an anti-inflammatory drug carrier. Porous β-TCP pellets were impregnated with an ethanolic solution of ibuprofen. The effects of contact time and concentration of ibuprofen solution on drug adsorption were studied. The ibuprofen adsorption equilibrium time was found to be one hour. The adsorption isotherms fitted to the Freundlich model, suggesting that the interaction between ibuprofen and β-TCP is weak. The physicochemical characterizations of loaded pellets confirmed that the reversible physisorption of ibuprofen on β-TCP pellets is due to Van der Waals forces, and this property was associated with the 100% ibuprofen release.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Polymer Surface Interaction Studies · Orthopaedic implants and arthroplasty
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. 10.1097/00003086-200202000-0000910.1097/00003086-200202000-00009 ↗
2. 10.1016/j.addr.2007.03.01110.1016/j.addr.2007.03.011 ↗
3. 10.1039/b610219k10.1039/b610219k ↗
4. Shinto Y · J. Bone Joint Surg. · 1992 · 74 · 60010.1302/0301-620X.74B4.1320622 ↗
5. 10.1021/cm702584d10.1021/cm702584d ↗
6. 10.1002/(SICI)1097-4636(19980615)40:4<560::AID-JBM7>3.0.CO;2-D10.1002/(SICI)1097-4636(19980615)40:4<560::AID-JBM7>3.0.CO;2-D ↗
7. 10.1016/j.biomaterials.2004.11.01010.1016/j.biomaterials.2004.11.010 ↗
8. Victor S P · J. Biomed. Nanotechnol. · 2008 · 4 · 203
9. re F · Mater. Sci. Eng. · 2008 · 59 · 3810.1016/j.mser.2007.12.001 ↗
10. 10.1007/s11999-009-0960-110.1007/s11999-009-0960-1 ↗
11. 10.1016/j.ceramint.2008.07.02210.1016/j.ceramint.2008.07.022 ↗
12. 10.1002/jbm.a.3139410.1002/jbm.a.31394 ↗
13. 10.1002/jor.2028410.1002/jor.20284 ↗
14. 10.1007/s10856-010-4127-010.1007/s10856-010-4127-0 ↗
15. 10.4028/www.scientific.net/KEM.284-286.39910.4028/www.scientific.net/KEM.284-286.399 ↗
16. 10.1016/j.jconrel.2004.03.00510.1016/j.jconrel.2004.03.005 ↗
17. 10.1021/cm001155910.1021/cm0011559 ↗
18. 10.1208/s12249-009-9252-z10.1208/s12249-009-9252-z ↗
19. 10.1016/j.talanta.2008.09.04610.1016/j.talanta.2008.09.046 ↗
20. 10.1016/S1773-2247(08)50084-010.1016/S1773-2247(08)50084-0 ↗
21. 10.1080/0363904090288229810.1080/03639040902882298 ↗
22. 10.1016/j.actbio.2009.07.04010.1016/j.actbio.2009.07.040 ↗
23. 10.1021/je025517010.1021/je0255170 ↗
24. 10.1016/S0039-9140(02)00058-910.1016/S0039-9140(02)00058-9 ↗
25. 10.1021/ja01287a04110.1021/ja01287a041 ↗
26. 10.1002/jps.260052121010.1002/jps.2600521210 ↗
27. 10.1021/ie50260a01810.1021/ie50260a018 ↗
28. 10.1016/S0955-2219(98)00057-010.1016/S0955-2219(98)00057-0 ↗
29. 10.1002/jbm.1034010.1002/jbm.10340 ↗
30. 10.1006/jcis.2001.745010.1006/jcis.2001.7450 ↗
31. 10.1016/j.actbio.2008.02.02710.1016/j.actbio.2008.02.027 ↗
32. 10.1016/S1075-6280(01)27008-610.1016/S1075-6280(01)27008-6 ↗
33. 10.1002/jps.2100710.1002/jps.21007 ↗
34. 10.1016/j.ejpb.2003.12.00710.1016/j.ejpb.2003.12.007 ↗
35. 10.1016/j.actbio.2010.01.01810.1016/j.actbio.2010.01.018 ↗
36. 10.1016/S0927-7757(01)00637-910.1016/S0927-7757(01)00637-9 ↗